Robinetin Modulates TGF-β/ERK Signaling and Tumor-Associated Phenotype in 3D Osteosarcoma Spheroids

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• Osteosarcoma (OS) is a primary bone cancer with limited treatment options and high toxicity from current chemotherapy.
• Existing 2D models do not fully capture OS complexity, hindering drug screening and therapeutic development.
• There is a critical need for advanced models and effective therapies for osteosarcoma.

Purpose of the Study:

• To develop and utilize a 3D osteosarcoma model to identify novel therapeutic strategies.
• To investigate the anticancer potential of robinetin in osteosarcoma.
• To compare the efficacy and toxicity of robinetin with doxorubicin in 3D OS models.

Main Methods:

• Development of 3D osteosarcoma spheroid and scaffold-based models.
• Gene expression analysis of pro-tumorigenic factors (IL6, OPN, MMP2, FN1).
• Assessment of TGF-β1 and p-ERK1/2 signaling pathway activation.
• Evaluation of robinetin's efficacy and toxicity in 3D models.

Main Results:

• The 3D OS model showed increased pro-tumorigenic gene expression and activation of TGF-β1/p-ERK1/2 pathways compared to 2D.
• Robinetin suppressed pro-tumorigenic genes and downregulated TGF-β1/p-ERK1/2 signaling.
• Robinetin demonstrated comparable efficacy to doxorubicin but with significantly lower toxicity to healthy cells.

Conclusions:

• Advanced 3D osteosarcoma models provide a more reliable platform for drug screening.
• Robinetin exhibits significant anticancer potential for osteosarcoma, targeting key pro-tumorigenic pathways.
• Robinetin represents a promising candidate for selective osteosarcoma therapy with reduced systemic toxicity.